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ARONJ Definition:  
• Current or previous antiresorptive or 
antiangiogenic agents        
 
• Exposed bone, intraoral or extraoral 
fistula in the maxillofacial region > 8 
weeks 
 
• No history of radiation therapy or 
metastatic disease (Ruggiero et al 2014) 
Incidence: 
• Australian incidence of spontaneous        
ARONJ: 
• IV bisphosphonates 1.15% 
• Oral bisphosphonates 0.04% 
 
• Incidence of ARONJ after extraction             
(Mavrokokki et al 2007): 
• IV bisphosphonates risk increased from 
1.15% to 9.1%. 
• Oral bisphosphonates risk increased      
from 0.04% to 0.34%. 
Medication Related Risk Factors: 
  • IV bisphosphonates  
• Oral bisphosphonates  
• RANK ligand inhibitor  
• Tyrosine kinase inhibitor and antiangiogenic monoclonal 
antibodies in conjunction with bisphosphonates             
(case reports) 
• Duration of antiresorptive drug exposure 
• Corticosteroids   
• Chemotherapy  
 
Local factors: 
• Operative treatment  
• Anatomy- Mandible>Maxilla  
• Overlying oral inflammatory disease  
• Tobacco use 
Pathogenesis:  
Remodelling suppression theory (Russell et al 2008, 
Russell & Rogers 1999) 
Inhibition of angiogenesis (Allen & Burr 
2008) Soft tissue toxicity (Santini et al 2003) 
Inflammation and infection Actinomyces spp (Hansen et al 
2007, Aguirre et al 2012) 
pH Otto et al 2010 
Immune dysfunction- IL-17 (Kikuiri et al 2010) 
Current Treatment Options: 
There remains no consensus regarding the 
optimal management of patients with      
ARONJ 
 
• Non-surgical: analgesia, chlorhexidine       
rinses, antibiotics  
 
• Surgical: minimally invasive surgical          
debridement- bleeding bone? use of        
VELscope? resective surgery 
Hypothesis  
The application of  rhBMP-2 is  
able to stimulate bone  
remodelling and angiogenesis.  
Thus, preventing the onset and 
development of MRONJ  
Growth Factor Delivery: 
 
Possible candidates for growth factor delivery:  
• Collagen sponge  
• Hydrogel 
• Fibrin Glue  
• Degradable polymer  
 
 
 
 
Need to satisfy three major criteria:  
1. Easily manipulated into small defects  
2. Able to provide a sustained release profile of rhBMP-2  
3. Able to stimulate cell proliferation 
Freudenberg et al 2009 
Histology of hydrogel              
construct 
Description of Experiment  
• 24 Sprague Dawley Rats received intravenous     
Zoledronic Acid (0.1mg/Kg) at two time points   
week 1 and week 4 
• Serum taken at week 1 (baseline), week 4 and    
euthanasia for CTX blood analysis 
• Right lower first molar removed at week 4 under 
General anaethesia  
• StarPEG/Heparin/RGD hydrogel with BMP placed 
into right molar defect at time of surgery.  
 
• 15μL volume hydrogel consisting of  
• Heparin-RGD(Arginylglycylaspartic acid) 6μL 
• 4μL PBS/ 4μL reconstituted BMP-2 (5μg) 
• 5μL StarPEG  
 
Serum C terminal telopeptide 
Rat Surgeries 
rhBMP-2 ELISA release  
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H&E bony necrosis  
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Osteocyte morphology an quantification 
Future work 
• Completion of Fluorescein stain to analyse newly       
formed bone osteon morphology  
• Analysis of MRONJ pig animal model with hydrogel   
rhBMP-2 and platelet rich plasma intervention groups  
 
 
